Definitive diagnosis of Alzheimer’s disease is not achieved until autopsy, yet its core biomarkers, amyloid-β and phosphorylated tau, have high diagnostic and prognostic value prior to the onset of dementia5 and have been previously associated with early brain microstructural changes in CU participants.74 It is important to note that we did not find overall group differences in amyloid or tau pathology, or for that matter, in any of the dMRI measures and CSF biomarkers assessed in our study. Here, MAPT is linked to Alzheimer disease.